{"id":352101,"date":"2025-08-26T07:09:07","date_gmt":"2025-08-26T07:09:07","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-korro-bio\/"},"modified":"2025-08-26T07:09:07","modified_gmt":"2025-08-26T07:09:07","slug":"how-to-buy-korro-bio","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/","title":{"rendered":"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334045,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-352101","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Korro Bio, Inc. (KRRO) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve RNA d\u00fczenleme teknolojisi ile g\u00fc\u00e7l\u00fc analist deste\u011fine sahip bu yenilik\u00e7i biyoteknoloji \u015firketinde yat\u0131r\u0131m f\u0131rsatlar\u0131n\u0131 ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Korro Bio, Inc. (KRRO) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve RNA d\u00fczenleme teknolojisi ile g\u00fc\u00e7l\u00fc analist deste\u011fine sahip bu yenilik\u00e7i biyoteknoloji \u015firketinde yat\u0131r\u0131m f\u0131rsatlar\u0131n\u0131 ke\u015ffedin."},"intro":"Keskin genetik t\u0131pta yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Korro Bio, Inc. (KRRO), genetik bozukluklar\u0131n tedavisinde devrim yaratma potansiyeline sahip RNA d\u00fczenleme teknolojisinin gelece\u011fini temsil ediyor. Bu klinik a\u015famadaki biyoteknoloji \u015firketi, \u00f6nemli y\u00fckseli\u015f potansiyeli ve \u00f6nemli riskler sunuyor - t\u0131bbi inovasyonun y\u00fcksek riskli d\u00fcnyas\u0131n\u0131 anlayan yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. Bu heyecan verici hisseyi portf\u00f6y\u00fcn\u00fcze nas\u0131l ekleyebilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Keskin genetik t\u0131pta yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Korro Bio, Inc. (KRRO), genetik bozukluklar\u0131n tedavisinde devrim yaratma potansiyeline sahip RNA d\u00fczenleme teknolojisinin gelece\u011fini temsil ediyor. Bu klinik a\u015famadaki biyoteknoloji \u015firketi, \u00f6nemli y\u00fckseli\u015f potansiyeli ve \u00f6nemli riskler sunuyor - t\u0131bbi inovasyonun y\u00fcksek riskli d\u00fcnyas\u0131n\u0131 anlayan yat\u0131r\u0131mc\u0131lar i\u00e7in m\u00fckemmel. Bu heyecan verici hisseyi portf\u00f6y\u00fcn\u00fcze nas\u0131l ekleyebilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Korro Bio Hissesi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2> <p>26 A\u011fustos 2025 itibar\u0131yla Korro Bio, Inc. (KRRO) hissesi <strong>20,39 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>11 Kas\u0131m 2025<\/strong> kesinlikle kritik - Korro Bio'nun bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu klinik a\u015famadaki biyoteknoloji kazan\u00e7 raporlar\u0131 fiyatlar\u0131 saatler i\u00e7inde dramatik \u015fekilde hareket ettirebilir.<\/p> <h3><strong>Klinik G\u00fcncellemeler KRRO Hissesini Nas\u0131l Hareket Ettirir<\/strong><\/h3> <p>12 A\u011fustos 2025 tarihli en son kazan\u00e7 raporu 25,8 milyon $ net zarar a\u00e7\u0131klad\u0131 ancak \u015firketin 119,6 milyon $ nakit rezervine sahip oldu\u011funu g\u00f6sterdi - bu, operasyonlar\u0131 2027 y\u0131l\u0131na kadar finanse etmek i\u00e7in yeterli. Bu \u00f6nemli nakit rezervleri ile klinik programlar\u0131n ilerlemesi kombinasyonu genellikle biyoteknoloji \u015firketleri i\u00e7in olumlu yat\u0131r\u0131mc\u0131 hissiyat\u0131 yarat\u0131r.<\/p> <p>Klinik deneme g\u00fcncellemeleri KRRO i\u00e7in \u00f6zellikle etkili oldu. \u015eirketin Alfa-1 Antitripsin Eksikli\u011fi hedefleyen KRRO-110 i\u00e7in Faz 1\/2a REWRITE denemesi, sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerin %80'inden fazlas\u0131n\u0131n dozland\u0131\u011f\u0131n\u0131 ve ciddi yan etki g\u00f6zlemlenmedi\u011fini g\u00f6stererek umut verici ilerleme kaydetti. 2025 ikinci yar\u0131s\u0131nda beklenen ara sonu\u00e7 b\u00fcy\u00fck bir kataliz\u00f6r olabilir.<\/p> <h3><strong>6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu<\/strong><\/h3> <p>Korro Bio hisseleri son alt\u0131 ayda klinik a\u015famadaki biyoteknoloji hisselerine \u00f6zg\u00fc \u00f6nemli volatilite ya\u015fad\u0131:<\/p> <ul> <li><strong>\u015eubat-Mart 2025<\/strong>: \u015eirket klinik deneme ba\u015flatmalar\u0131na haz\u0131rlan\u0131rken fiyat 25-30 $ aral\u0131\u011f\u0131nda konsolide oldu<\/li> <li><strong>Nisan-May\u0131s 2025<\/strong>: Piyasa genelinde biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle yakla\u015f\u0131k 15-18 $ aral\u0131\u011f\u0131na d\u00fc\u015f\u00fc\u015f<\/li> <li><strong>Haziran 2025<\/strong>: %20 personel azalt\u0131m\u0131 i\u00e7eren stratejik yeniden yap\u0131lanma duyurusu ge\u00e7ici bask\u0131 yaratt\u0131 ancak tedbirli maliyet y\u00f6netimi olarak g\u00f6r\u00fcld\u00fc<\/li> <li><strong>Temmuz 2025<\/strong>: Klinik ilerleme devam ederken ve EMA Yetim \u0130la\u00e7 Tasar\u0131m\u0131 al\u0131n\u0131rken mevcut seviyelere, yakla\u015f\u0131k 20 $'a toparlanma<\/li> <li><strong>A\u011fustos 2025<\/strong>: Yakla\u015fan klinik veriler i\u00e7in beklentilerle 20 $ civar\u0131nda istikrar<\/li> <\/ul> <p>Bu model, klasik biyoteknoloji hisse davran\u0131\u015f\u0131n\u0131 g\u00f6steriyor - belirsizlikte keskin d\u00fc\u015f\u00fc\u015fler, olumlu klinik geli\u015fmelerle h\u0131zl\u0131 toparlanmalar.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve klinik zaman \u00e7izelgesi beklentilerine dayanarak:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 40-60 $ aral\u0131\u011f\u0131 (y\u00fczde 100-200 potansiyel art\u0131\u015f)<\/p> <ul> <li>Kataliz\u00f6rler: Ara REWRITE deneme verileri, potansiyel ortakl\u0131k geni\u015flemeleri<\/li> <li><strong>SONU\u00c7: R\u0130SK TOLERANSI OLAN YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong><\/li> <\/ul> <p><strong>2026 Projeksiyonu<\/strong>: 75-120 $ aral\u0131\u011f\u0131<\/p> <ul> <li>Olumlu Faz 2 verileri ve Faz 3 ilerlemesi varsay\u0131m\u0131<\/li> <li>Novo Nordisk ortakl\u0131\u011f\u0131 ek de\u011fer sa\u011flayabilir<\/li> <\/ul> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 150-250 $ aral\u0131\u011f\u0131<\/p> <ul> <li>Geli\u015fim ba\u015far\u0131l\u0131 olursa ilk ticari \u00fcr\u00fcn onay\u0131 potansiyeli<\/li> <li>Ek genetik bozukluklara geni\u015fleme<\/li> <\/ul> <p><strong>2030 Vizyonu<\/strong>: 300 $+ potansiyel<\/p> <ul> <li>Nadir hastal\u0131k pazarlar\u0131nda birden fazla ticari \u00fcr\u00fcn<\/li> <li>RNA d\u00fczenleme teknolojisinde yerle\u015fik liderlik<\/li> <\/ul> <p>Bu ilerleme ba\u015far\u0131l\u0131 klinik geli\u015fime ba\u011fl\u0131d\u0131r - t\u00fcm biyoteknoloji yat\u0131r\u0131mlar\u0131 i\u00e7in ana risk fakt\u00f6r\u00fc.<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3><strong>Her Yat\u0131r\u0131mc\u0131n\u0131n Dikkate Almas\u0131 Gereken Riskler<\/strong><\/h3> <ol> <li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: En \u00f6nemli risk - ba\u015far\u0131s\u0131z denemeler tek g\u00fcnde %80'den fazla d\u00fc\u015f\u00fc\u015fe neden olabilir<\/li> <li><strong>Nakit T\u00fcketimi<\/strong>: Mevcut rezervlere ra\u011fmen ek finansman gerekebilir, bu da mevcut hissedarlar\u0131n seyrelmesine yol a\u00e7abilir<\/li> <li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA ve EMA onaylar\u0131 asla garanti de\u011fildir, \u00f6zellikle yeni teknolojiler i\u00e7in<\/li> <li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri rakip RNA terapileri geli\u015ftiriyor<\/li> <li><strong>Piyasa Volatilitesi<\/strong>: Biyoteknoloji hisseleri genel piyasa hissiyat\u0131 ve faiz oran\u0131 de\u011fi\u015fikliklerine \u00e7ok duyarl\u0131d\u0131r<\/li> <\/ol> <h3><strong>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/h3> <ol> <li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: 119,6 milyon $ 2027'ye kadar finansman sa\u011flar, k\u0131sa vadeli seyrelme riskini azalt\u0131r<\/li> <li><strong>EMA Yetim \u0130la\u00e7 Tasar\u0131m\u0131<\/strong>: Avrupa'da ticari potansiyeli art\u0131r\u0131r ve reg\u00fclasyon avantajlar\u0131 sa\u011flar<\/li> <li><strong>Novo Nordisk Ortakl\u0131\u011f\u0131<\/strong>: 530 milyon $ i\u015f birli\u011fi do\u011frulama ve finansal destek sa\u011flar<\/li> <li><strong>Klinik \u0130lerleme<\/strong>: Sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerde %80'den fazla dozlama tamamland\u0131 ve temiz g\u00fcvenlik profili<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: RNA terap\u00f6tik pazar\u0131 2030'a kadar %15+ CAGR ile b\u00fcy\u00fcmesi bekleniyor<\/li> <\/ol> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 KRRO gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li> <li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yerine k\u00fc\u00e7\u00fck par\u00e7alar halinde almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>11 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7 tarihini i\u015faretleyin ve olas\u0131 volatiliteye haz\u0131rl\u0131kl\u0131 olun<\/li> <li><strong>Klinik Kataliz\u00f6rleri Takip Edin<\/strong>: 2025 sonlar\u0131nda beklenen ara veri sonu\u00e7lar\u0131n\u0131 izleyin<\/li> <li><strong>Esprili Yakla\u015f\u0131m<\/strong>: \"KRRO ticareti, parlak bir bilim insan\u0131yla ili\u015fki ya\u015famak gibidir - heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. G\u00fcvenlik g\u00f6zl\u00fc\u011f\u00fcn\u00fcz\u00fc takmay\u0131 unutmay\u0131n!\"<\/li> <\/ol> <h2>\u2705 Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve rekabet\u00e7i \u00fccretler sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Tamamen riske atmaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"KRRO\" Aramas\u0131 Yap\u0131n<\/td><td>Korro Bio i\u00e7in tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Dalgal\u0131 hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Emir detaylar\u0131n\u0131 sonland\u0131rmadan \u00f6nce \u00e7ift kontrol edin<\/td><\/tr> <\/tbody> <\/table> <h3><strong>Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Neden Uygun?<\/strong><\/h3> <p>Pocket Option, Korro Bio gibi \u015firketlerle ilgilenenler i\u00e7in benzersiz avantajlar sunar:<\/p> <ul> <li><strong>Minimum 5 $ depozito<\/strong> - Dalgal\u0131 hisselerde k\u00fc\u00e7\u00fck pozisyonlarla stratejileri test etmek i\u00e7in m\u00fckemmel<\/li> <li><strong>H\u0131zl\u0131 hesap do\u011frulama<\/strong> - Zaman hassas f\u0131rsatlar ortaya \u00e7\u0131kt\u0131\u011f\u0131nda h\u0131zl\u0131ca ba\u015flay\u0131n<\/li> <li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> - Ba\u015far\u0131l\u0131 i\u015flemlerden karlar\u0131 esnek \u015fekilde \u00e7ekin<\/li> <li><strong>E\u011fitim kaynaklar\u0131<\/strong> - Biyoteknoloji yat\u0131r\u0131m\u0131 hakk\u0131nda <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerinden \u00f6\u011frenin<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te Korro Bio: RNA D\u00fczenleme \u00d6nc\u00fcs\u00fc<\/h2> <p>Korro Bio, RNA d\u00fczenleme terap\u00f6tikleri alan\u0131nda lider konumunu g\u00fc\u00e7lendiriyor. \u015eirketin OPERA platformu, DNA yerine RNA'y\u0131 d\u00fczenleyerek genetik bozukluklar\u0131 tedavi etmeye y\u00f6nelik yenilik\u00e7i bir yakla\u015f\u0131m sunuyor ve g\u00fcvenlik ile geri d\u00f6nd\u00fcr\u00fclebilirlik a\u00e7\u0131s\u0131ndan avantajlar sa\u011fl\u0131yor.<\/p> <p>\u015eu anda Alfa-1 Antitripsin Eksikli\u011fi \u00fczerine odaklan\u0131lmas\u0131, s\u0131n\u0131rl\u0131 tedavi se\u00e7ene\u011fi olan \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiyaca yan\u0131t veriyor. Novo Nordisk ile ortakl\u0131k sadece finansal destek sa\u011flamakla kalm\u0131yor, ayn\u0131 zamanda d\u00fcnyan\u0131n \u00f6nde gelen diyabet ve metabolik hastal\u0131k \u015firketlerinden biri taraf\u0131ndan onaylanmay\u0131 da beraberinde getiriyor.<\/p> <p><strong>2025'ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: May\u0131s 2025'te Korro Bio'nun stratejik yeniden yap\u0131lanmas\u0131, %20 personel azalt\u0131m\u0131yla zor olsa da, 2027'ye kadar OPERA platformu arac\u0131l\u0131\u011f\u0131yla iki doku tipinde \u00fc\u00e7 klinik varl\u0131k hedefleyen '3-2-1' stratejisini h\u0131zland\u0131rmak i\u00e7in \u00f6zel olarak tasarland\u0131. Bu odaklanm\u0131\u015f yakla\u015f\u0131m, sermaye yo\u011fun biyoteknoloji sekt\u00f6r\u00fcnde disiplinli kaynak tahsisini g\u00f6steriyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Korro Bio Hissesi: G\u00fcncel Fiyat ve Piyasa Konumu<\/h2>\n<p>26 A\u011fustos 2025 itibar\u0131yla Korro Bio, Inc. (KRRO) hissesi <strong>20,39 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Takviminize not edin: <strong>11 Kas\u0131m 2025<\/strong> kesinlikle kritik &#8211; Korro Bio&#8217;nun bir sonraki \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih. Tarihsel olarak, bu klinik a\u015famadaki biyoteknoloji kazan\u00e7 raporlar\u0131 fiyatlar\u0131 saatler i\u00e7inde dramatik \u015fekilde hareket ettirebilir.<\/p>\n<h3><strong>Klinik G\u00fcncellemeler KRRO Hissesini Nas\u0131l Hareket Ettirir<\/strong><\/h3>\n<p>12 A\u011fustos 2025 tarihli en son kazan\u00e7 raporu 25,8 milyon $ net zarar a\u00e7\u0131klad\u0131 ancak \u015firketin 119,6 milyon $ nakit rezervine sahip oldu\u011funu g\u00f6sterdi &#8211; bu, operasyonlar\u0131 2027 y\u0131l\u0131na kadar finanse etmek i\u00e7in yeterli. Bu \u00f6nemli nakit rezervleri ile klinik programlar\u0131n ilerlemesi kombinasyonu genellikle biyoteknoloji \u015firketleri i\u00e7in olumlu yat\u0131r\u0131mc\u0131 hissiyat\u0131 yarat\u0131r.<\/p>\n<p>Klinik deneme g\u00fcncellemeleri KRRO i\u00e7in \u00f6zellikle etkili oldu. \u015eirketin Alfa-1 Antitripsin Eksikli\u011fi hedefleyen KRRO-110 i\u00e7in Faz 1\/2a REWRITE denemesi, sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerin %80&#8217;inden fazlas\u0131n\u0131n dozland\u0131\u011f\u0131n\u0131 ve ciddi yan etki g\u00f6zlemlenmedi\u011fini g\u00f6stererek umut verici ilerleme kaydetti. 2025 ikinci yar\u0131s\u0131nda beklenen ara sonu\u00e7 b\u00fcy\u00fck bir kataliz\u00f6r olabilir.<\/p>\n<h3><strong>6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu<\/strong><\/h3>\n<p>Korro Bio hisseleri son alt\u0131 ayda klinik a\u015famadaki biyoteknoloji hisselerine \u00f6zg\u00fc \u00f6nemli volatilite ya\u015fad\u0131:<\/p>\n<ul>\n<li><strong>\u015eubat-Mart 2025<\/strong>: \u015eirket klinik deneme ba\u015flatmalar\u0131na haz\u0131rlan\u0131rken fiyat 25-30 $ aral\u0131\u011f\u0131nda konsolide oldu<\/li>\n<li><strong>Nisan-May\u0131s 2025<\/strong>: Piyasa genelinde biyoteknoloji sekt\u00f6r\u00fcndeki zay\u0131fl\u0131k nedeniyle yakla\u015f\u0131k 15-18 $ aral\u0131\u011f\u0131na d\u00fc\u015f\u00fc\u015f<\/li>\n<li><strong>Haziran 2025<\/strong>: %20 personel azalt\u0131m\u0131 i\u00e7eren stratejik yeniden yap\u0131lanma duyurusu ge\u00e7ici bask\u0131 yaratt\u0131 ancak tedbirli maliyet y\u00f6netimi olarak g\u00f6r\u00fcld\u00fc<\/li>\n<li><strong>Temmuz 2025<\/strong>: Klinik ilerleme devam ederken ve EMA Yetim \u0130la\u00e7 Tasar\u0131m\u0131 al\u0131n\u0131rken mevcut seviyelere, yakla\u015f\u0131k 20 $&#8217;a toparlanma<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: Yakla\u015fan klinik veriler i\u00e7in beklentilerle 20 $ civar\u0131nda istikrar<\/li>\n<\/ul>\n<p>Bu model, klasik biyoteknoloji hisse davran\u0131\u015f\u0131n\u0131 g\u00f6steriyor &#8211; belirsizlikte keskin d\u00fc\u015f\u00fc\u015fler, olumlu klinik geli\u015fmelerle h\u0131zl\u0131 toparlanmalar.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve klinik zaman \u00e7izelgesi beklentilerine dayanarak:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 40-60 $ aral\u0131\u011f\u0131 (y\u00fczde 100-200 potansiyel art\u0131\u015f)<\/p>\n<ul>\n<li>Kataliz\u00f6rler: Ara REWRITE deneme verileri, potansiyel ortakl\u0131k geni\u015flemeleri<\/li>\n<li><strong>SONU\u00c7: R\u0130SK TOLERANSI OLAN YATIRIMCILAR \u0130\u00c7\u0130N G\u00dc\u00c7L\u00dc ALIM<\/strong><\/li>\n<\/ul>\n<p><strong>2026 Projeksiyonu<\/strong>: 75-120 $ aral\u0131\u011f\u0131<\/p>\n<ul>\n<li>Olumlu Faz 2 verileri ve Faz 3 ilerlemesi varsay\u0131m\u0131<\/li>\n<li>Novo Nordisk ortakl\u0131\u011f\u0131 ek de\u011fer sa\u011flayabilir<\/li>\n<\/ul>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 150-250 $ aral\u0131\u011f\u0131<\/p>\n<ul>\n<li>Geli\u015fim ba\u015far\u0131l\u0131 olursa ilk ticari \u00fcr\u00fcn onay\u0131 potansiyeli<\/li>\n<li>Ek genetik bozukluklara geni\u015fleme<\/li>\n<\/ul>\n<p><strong>2030 Vizyonu<\/strong>: 300 $+ potansiyel<\/p>\n<ul>\n<li>Nadir hastal\u0131k pazarlar\u0131nda birden fazla ticari \u00fcr\u00fcn<\/li>\n<li>RNA d\u00fczenleme teknolojisinde yerle\u015fik liderlik<\/li>\n<\/ul>\n<p>Bu ilerleme ba\u015far\u0131l\u0131 klinik geli\u015fime ba\u011fl\u0131d\u0131r &#8211; t\u00fcm biyoteknoloji yat\u0131r\u0131mlar\u0131 i\u00e7in ana risk fakt\u00f6r\u00fc.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3><strong>Her Yat\u0131r\u0131mc\u0131n\u0131n Dikkate Almas\u0131 Gereken Riskler<\/strong><\/h3>\n<ol>\n<li><strong>Klinik Deneme Ba\u015far\u0131s\u0131zl\u0131\u011f\u0131<\/strong>: En \u00f6nemli risk &#8211; ba\u015far\u0131s\u0131z denemeler tek g\u00fcnde %80&#8217;den fazla d\u00fc\u015f\u00fc\u015fe neden olabilir<\/li>\n<li><strong>Nakit T\u00fcketimi<\/strong>: Mevcut rezervlere ra\u011fmen ek finansman gerekebilir, bu da mevcut hissedarlar\u0131n seyrelmesine yol a\u00e7abilir<\/li>\n<li><strong>Reg\u00fclasyon Engelleri<\/strong>: FDA ve EMA onaylar\u0131 asla garanti de\u011fildir, \u00f6zellikle yeni teknolojiler i\u00e7in<\/li>\n<li><strong>Rekabet<\/strong>: Daha b\u00fcy\u00fck ila\u00e7 \u015firketleri rakip RNA terapileri geli\u015ftiriyor<\/li>\n<li><strong>Piyasa Volatilitesi<\/strong>: Biyoteknoloji hisseleri genel piyasa hissiyat\u0131 ve faiz oran\u0131 de\u011fi\u015fikliklerine \u00e7ok duyarl\u0131d\u0131r<\/li>\n<\/ol>\n<h3><strong>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/strong><\/h3>\n<ol>\n<li><strong>G\u00fc\u00e7l\u00fc Nakit Pozisyonu<\/strong>: 119,6 milyon $ 2027&#8217;ye kadar finansman sa\u011flar, k\u0131sa vadeli seyrelme riskini azalt\u0131r<\/li>\n<li><strong>EMA Yetim \u0130la\u00e7 Tasar\u0131m\u0131<\/strong>: Avrupa&#8217;da ticari potansiyeli art\u0131r\u0131r ve reg\u00fclasyon avantajlar\u0131 sa\u011flar<\/li>\n<li><strong>Novo Nordisk Ortakl\u0131\u011f\u0131<\/strong>: 530 milyon $ i\u015f birli\u011fi do\u011frulama ve finansal destek sa\u011flar<\/li>\n<li><strong>Klinik \u0130lerleme<\/strong>: Sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerde %80&#8217;den fazla dozlama tamamland\u0131 ve temiz g\u00fcvenlik profili<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: RNA terap\u00f6tik pazar\u0131 2030&#8217;a kadar %15+ CAGR ile b\u00fcy\u00fcmesi bekleniyor<\/li>\n<\/ol>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 KRRO gibi y\u00fcksek riskli biyoteknoloji hisselerine ay\u0131rmay\u0131n<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yerine k\u00fc\u00e7\u00fck par\u00e7alar halinde almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>11 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7 tarihini i\u015faretleyin ve olas\u0131 volatiliteye haz\u0131rl\u0131kl\u0131 olun<\/li>\n<li><strong>Klinik Kataliz\u00f6rleri Takip Edin<\/strong>: 2025 sonlar\u0131nda beklenen ara veri sonu\u00e7lar\u0131n\u0131 izleyin<\/li>\n<li><strong>Esprili Yakla\u015f\u0131m<\/strong>: &#8220;KRRO ticareti, parlak bir bilim insan\u0131yla ili\u015fki ya\u015famak gibidir &#8211; heyecan verici at\u0131l\u0131mlar ve ara s\u0131ra laboratuvar patlamalar\u0131. G\u00fcvenlik g\u00f6zl\u00fc\u011f\u00fcn\u00fcz\u00fc takmay\u0131 unutmay\u0131n!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve rekabet\u00e7i \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Tamamen riske atmaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;KRRO&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Korro Bio i\u00e7in tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Dalgal\u0131 hisselerde giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Emir detaylar\u0131n\u0131 sonland\u0131rmadan \u00f6nce \u00e7ift kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h3><strong>Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Neden Uygun?<\/strong><\/h3>\n<p>Pocket Option, Korro Bio gibi \u015firketlerle ilgilenenler i\u00e7in benzersiz avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum 5 $ depozito<\/strong> &#8211; Dalgal\u0131 hisselerde k\u00fc\u00e7\u00fck pozisyonlarla stratejileri test etmek i\u00e7in m\u00fckemmel<\/li>\n<li><strong>H\u0131zl\u0131 hesap do\u011frulama<\/strong> &#8211; Zaman hassas f\u0131rsatlar ortaya \u00e7\u0131kt\u0131\u011f\u0131nda h\u0131zl\u0131ca ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> &#8211; Ba\u015far\u0131l\u0131 i\u015flemlerden karlar\u0131 esnek \u015fekilde \u00e7ekin<\/li>\n<li><strong>E\u011fitim kaynaklar\u0131<\/strong> &#8211; Biyoteknoloji yat\u0131r\u0131m\u0131 hakk\u0131nda <a href=\"\/blog\">Pocket Option blog<\/a> \u00fczerinden \u00f6\u011frenin<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Korro Bio: RNA D\u00fczenleme \u00d6nc\u00fcs\u00fc<\/h2>\n<p>Korro Bio, RNA d\u00fczenleme terap\u00f6tikleri alan\u0131nda lider konumunu g\u00fc\u00e7lendiriyor. \u015eirketin OPERA platformu, DNA yerine RNA&#8217;y\u0131 d\u00fczenleyerek genetik bozukluklar\u0131 tedavi etmeye y\u00f6nelik yenilik\u00e7i bir yakla\u015f\u0131m sunuyor ve g\u00fcvenlik ile geri d\u00f6nd\u00fcr\u00fclebilirlik a\u00e7\u0131s\u0131ndan avantajlar sa\u011fl\u0131yor.<\/p>\n<p>\u015eu anda Alfa-1 Antitripsin Eksikli\u011fi \u00fczerine odaklan\u0131lmas\u0131, s\u0131n\u0131rl\u0131 tedavi se\u00e7ene\u011fi olan \u00f6nemli kar\u015f\u0131lanmam\u0131\u015f t\u0131bbi ihtiyaca yan\u0131t veriyor. Novo Nordisk ile ortakl\u0131k sadece finansal destek sa\u011flamakla kalm\u0131yor, ayn\u0131 zamanda d\u00fcnyan\u0131n \u00f6nde gelen diyabet ve metabolik hastal\u0131k \u015firketlerinden biri taraf\u0131ndan onaylanmay\u0131 da beraberinde getiriyor.<\/p>\n<p><strong>2025&#8217;ten \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: May\u0131s 2025&#8217;te Korro Bio&#8217;nun stratejik yeniden yap\u0131lanmas\u0131, %20 personel azalt\u0131m\u0131yla zor olsa da, 2027&#8217;ye kadar OPERA platformu arac\u0131l\u0131\u011f\u0131yla iki doku tipinde \u00fc\u00e7 klinik varl\u0131k hedefleyen &#8216;3-2-1&#8217; stratejisini h\u0131zland\u0131rmak i\u00e7in \u00f6zel olarak tasarland\u0131. Bu odaklanm\u0131\u015f yakla\u015f\u0131m, sermaye yo\u011fun biyoteknoloji sekt\u00f6r\u00fcnde disiplinli kaynak tahsisini g\u00f6steriyor.<\/p>\n"},"faq":[{"question":"Korro Bio hisseleri nereden al\u0131nabilir?","answer":"Korro Bio hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden 'KRRO' sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Korro Bio'nun klinik denemeleri ne durumda?","answer":"Korro Bio'nun Faz 1\/2a REWRITE denemesi Alfa-1 Antitripsin Eksikli\u011fi i\u00e7in umut verici ilerleme kaydetti. Sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerin %80'inden fazlas\u0131 dozland\u0131 ve ciddi yan etki g\u00f6zlemlenmedi."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler dikkate al\u0131nmal\u0131?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit t\u00fcketimi, reg\u00fclasyon engelleri, rekabet ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"Korro Bio'nun gelecekteki fiyat beklentileri nelerdir?","answer":"Analistlere g\u00f6re 2025 sonunda 40-60 $, 2026'da 75-120 $, 2028'de 150-250 $ ve 2030'da 300 $ \u00fczeri fiyat potansiyeli bulunmaktad\u0131r."},{"question":"Yeni ba\u015flayanlar Korro Bio hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 ay\u0131rmay\u0131n, k\u00fc\u00e7\u00fck al\u0131mlar yap\u0131n, \u00f6nemli tarihleri takip edin ve klinik geli\u015fmeleri izleyin."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Korro Bio hisseleri nereden al\u0131nabilir?","answer":"Korro Bio hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden 'KRRO' sembol\u00fc ile al\u0131m yapabilirsiniz."},{"question":"Korro Bio'nun klinik denemeleri ne durumda?","answer":"Korro Bio'nun Faz 1\/2a REWRITE denemesi Alfa-1 Antitripsin Eksikli\u011fi i\u00e7in umut verici ilerleme kaydetti. Sa\u011fl\u0131kl\u0131 g\u00f6n\u00fcll\u00fclerin %80'inden fazlas\u0131 dozland\u0131 ve ciddi yan etki g\u00f6zlemlenmedi."},{"question":"Yat\u0131r\u0131m yaparken hangi riskler dikkate al\u0131nmal\u0131?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit t\u00fcketimi, reg\u00fclasyon engelleri, rekabet ve piyasa volatilitesi ba\u015fl\u0131ca risklerdir."},{"question":"Korro Bio'nun gelecekteki fiyat beklentileri nelerdir?","answer":"Analistlere g\u00f6re 2025 sonunda 40-60 $, 2026'da 75-120 $, 2028'de 150-250 $ ve 2030'da 300 $ \u00fczeri fiyat potansiyeli bulunmaktad\u0131r."},{"question":"Yeni ba\u015flayanlar Korro Bio hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 ay\u0131rmay\u0131n, k\u00fc\u00e7\u00fck al\u0131mlar yap\u0131n, \u00f6nemli tarihleri takip edin ve klinik geli\u015fmeleri izleyin."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T07:09:07+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-26T07:09:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/\",\"name\":\"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"datePublished\":\"2025-08-26T07:09:07+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/","og_locale":"tr_TR","og_type":"article","og_title":"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-26T07:09:07+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-26T07:09:07+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/","name":"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r - Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","datePublished":"2025-08-26T07:09:07+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals7.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-korro-bio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Korro Bio, Inc. (KRRO) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Korro Bio, Inc. (KRRO) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":352099,"slug":"how-to-buy-korro-bio","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Korro Bio, Inc. (KRRO) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Korro Bio, Inc. (KRRO)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-korro-bio\/"},"pt_AA":{"locale":"pt_AA","id":352098,"slug":"how-to-buy-korro-bio","post_title":"Como comprar a\u00e7\u00f5es da Korro Bio, Inc. (KRRO) - Investimento em a\u00e7\u00f5es da Korro Bio, Inc. (KRRO)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-korro-bio\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352101","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=352101"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352101\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334045"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=352101"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=352101"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=352101"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}